TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Psychotherapy and Pharmacotherapy in the Treatment of Erectile Dysfunction: A Pilot Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SEQUENTIAL
- Observational Model: None
- Primary Purpose: OTHER
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Men diagnosed with erectile dysfunction~2. Must be in the age range of 18 to 39 years~3. Must be in a stable heterosexual relationship~4. Must not be suffering from any medical or psychiatric illness~Exclusion Criteria:~1. Men not meeting criteria of diagnosis of erectile dysfunction~2. Men not in a heterosexual relationship~3. Men of or above the age of 40 years~4. Men diagnosed with any medical or psychiatric illness or obese men

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 39 Years
- Healthy Volunteers: f

Study Arms:
- Group A (Type: EXPERIMENTAL): The cognitive behavior psychotherapy was administered to participants in this treatment arm.
- Control Group (Type: ACTIVE_COMPARATOR): This group received the administration of pharmacotherapy (PDE5i) for treatment of Erectile Dysfunction.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Postoperative CCRT With Docetaxel vs Cisplatin in High Risk Oral Cavity Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* 1.Histologically confirmed squamous cell carcinoma of the oral cavity 2. Gross total resection, with pathology demonstrating one or more of the following risk factors:~  1. Histologic extracapsular nodal extension~ 2. Histologic involvement of ≥ 2 regional lymph nodes~ 3. Invasive cancer is seen on microscopic evaluation of the resection margin, with no evidence of gross tumor residual 3. No evidence of distant metastases 4. No synchronous or concurrent head and neck primary tumors 5. ECOG 0-1 6. Adequate organ function including the following:~  <!-- -->~  1. Absolute neutrophil count (ANC) \>= 1.5 \* 10\^9/l~ 2. Platelets count \>= 100 \* 10\^9/l~ 3. Hemoglobin \>= 10 g/dl~ 4. AST and ALT \<= 2.5 times institutional upper limit of normal (ULN)~ 5. Total bilirubin \<= 1.5 times institutional ULN~ 6. Creatinine clearance \>= 50 ml/min~ 7. Serum creatine \<= 1 times ULN 7.Signed written informed consent~Exclusion Criteria:~* 1. Evidence of distant metastasis 2. Prior chemotherapy or anti-cancer biologic therapy for any type of cancer, or prior radiotherapy to the head and neck region 3. Other previous cancer, except for in situ cervical cancer and cutaneous basal cell carcinoma 4. Pregnant or breast-feeding females, or females and males of childbearing potential not taking adequate contraceptive measures 5.Presence of an uncontrolled concomitant illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac arrhythmia

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Experimental (Type: EXPERIMENTAL): Concurrent Chemoradiotherapy With Docetaxel and IMRT
- Control (Type: ACTIVE_COMPARATOR): Concurrent Chemoradiotherapy With Cisplatinum and IMRT

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clarithromycin as Adjuvant to Periodontal Debridement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diagnosis of Generalized Aggressive Periodontitis~* presence of ≥20 teeth~* presence of ≥ 6 sites presenting probing depth (PD) ≥5mm with bleeding on probing (BOP) and ≥2 sites with PD ≥7mm (including incisors and first molars, in addition to two other non-contiguous teeth between them)~* good general health~* \<35 years of age~* agree to participate in the study and sign a written consent~Exclusion Criteria:~* pregnant or lactating~* suffering from any other systemic disease (e.g. cardiovascular, diabetes, blood dyscrasias, immunodeficiency, etc) which could alter the course of periodontal disease~* received antimicrobials in the previous 6 months~* taking long-term anti-inflammatory drugs~* received a course of periodontal treatment within the last 12 months~* smoked

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 35 Years
- Healthy Volunteers: t

Study Arms:
- clarithromycin group (Type: ACTIVE_COMPARATOR): 20 subjects that received one-stage full-mouth ultrasonic debridement (FMUD) associated with clarithromycin (500 mg - 12/12 hours) for 3 days.
- placebo group (Type: PLACEBO_COMPARATOR): 20 subjects that received FMUD associated with placebo (members took with placebo 500 mg b.i.d. for 3 days).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: OTO-201 for the Treatment of Middle Ear Effusion in Pediatric Subjects Requiring Tympanostomy Tube Placement

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria includes, but is not limited to:~* Subject is a male or female aged 6 months to 17 years, inclusive~* Subject has a clinical diagnosis of bilateral middle ear effusion requiring tympanostomy tube placement~* Subject's caregiver is willing to comply with the protocol and attend all study visits~Exclusion Criteria includes, but is not limited to:~* Subject has a history of prior ear or mastoid surgery, not including myringotomy or myringotomy with tympanostomy tube placement~* Subject has a history of sensorineural hearing loss~* Subject has a history of chronic or recurrent bacterial infections other than otitis media that likely will require treatment with antibiotics during the course of the study

- Gender: ALL
- Minimum Age: 6 Months
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- OTO-201 (Type: EXPERIMENTAL): OTO-201: Single, intratympanic injection:~One injection of 6 mg OTO-201 (ciprofloxacin in poloxamer 407) into each ear during surgery.
- Sham (Type: SHAM_COMPARATOR): Sham: Simulated single, intratympanic injection:~One sham injection into each ear during surgery.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cisplatin With or Without Sodium Thiosulfate in Treating Young Patients With Stage I, II, or III Childhood Liver Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Histologically confirmed newly diagnosed hepatoblastoma~* Standard risk hepatoblastoma (Pretext I,II,III)~* Age ≤ 18 years and \> 1 month~* Written informed consent and national/local ethics committee and regulatory approval~* Centre/country willing and able to organise audiometry at the minimum required quality standard and to provide the contact details of the Consultant Audiologist or Ear Nose and Throat Surgeon who will take the responsibility for seeing that this is done~* Ability to comply with requirements for submission of material for central review~* For females of child-bearing potential, a negative pregnancy test prior to study treatment is required.~* Any patient who is of reproductive age should agree to use adequate contraception for the duration of the trial.~Exclusion:~High risk hepatoblastoma~* Hepatocellular carcinoma~* Treatment starting more than 15 days from written biopsy report~* Abnormal renal function~* Any previous chemotherapy~* Recurrent disease~* Previous hypersensitivity to STS~* Patient unable to follow the protocol for any reason

- Gender: ALL
- Minimum Age: 1 Month
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- Arm I (cisplatin) (Type: ACTIVE_COMPARATOR): Neoadjuvant and adjuvant cisplatin: patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 2 weeks for 4 courses. Patients with progressive disease after course 4 are taken off study. Patients without evidence of disease progression proceed to surgery. Beginning within 3 weeks after surgery, patients receive cisplatin IV over 6 hours on day 1. Treatment repeats every 2 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.
- Arm II (cisplatin + STS) (Type: EXPERIMENTAL): Neoadjuvant and adjuvant cisplatin and sodium thiosulphate (STS): patients receive cisplatin IV over 6 hours and sodium thiosulphate IV over 15 minutes (beginning 6 hours after completion of cisplatin) on day 1. Treatment repeats every 2 weeks for 4 courses. Patients with progressive disease after course 4 are taken off study. Patients without evidence of disease progression proceed to surgery. Beginning within 3 weeks after surgery, patients receive cisplatin IV over 6 hours and sodium thiosulphate IV over 15 minutes (as in neoadjuvant therapy) on day 1. Treatment repeats every 2 weeks for 2 courses in the absence of disease progression or unacceptable toxicity.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Look at Day to Day Changes in Lung Function in COPD Subjects Taking Albuterol/Salbutamol and Ipratropium

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Subjects must give their signed and dated written informed consent to participate.~* Subjects 40 years of age or older at Visit 1.~* Male or female subjects .~* An established clinical history of COPD.~* Current or former cigarette smokers with a history of cigarette smoking of \>=10 pack-years at Visit 1.~* A post-albuterol/salbutamol FEV1/FVC ratio of \<0.70 and a post-albuterol/salbutamol FEV1 of \>=30 and \<= 70% of predicted normal values at Visit 1 calculated using NHANES III reference equations .~Exclusion Criteria:~* A current diagnosis of asthma~* Women who are pregnant of lactating or are planning on becoming pregnant during the study.~* Hospitalization for COPD or pneumonia within 12 weeks prior to Visit 1.~* Participation in pulmonary rehabilitation

- Gender: ALL
- Minimum Age: 40 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Albuterol/salbutamol followed by ipratropium (Type: ACTIVE_COMPARATOR): Subjects will recieve daily albuterol/salbutamol followed by ipratropium which will be adminstered one hour after adminstration of albuterol/salbutamol
- Ipratropium followed by albuterol/salbutamol (Type: ACTIVE_COMPARATOR): Subjects will recieve daily ipratropium followed by albuterol/salbutamol which will be adminstered one hour after adminstration of ipratropium

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tetracycline (Doxycycline) and Post Myocardial Infarction Remodeling

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Acute myocardial infarction~* Left ventricular ejection fraction less than 40%~Exclusion Criteria:~* No written consensus~* Allergy to tetracycline~* Mechanical complication of AMI~* Previous myocardial infarction~* Valvular and/or myocardiopathy known or suspected~* Renal failure (creatinine above 2 mg/dL)~* Connective tissue disease~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Doxycycline (Type: EXPERIMENTAL): Active drug 100 mg bid for seven days in pts with AMI treated with Primary PCI and current medical therapy
- Standard Therapy (Type: ACTIVE_COMPARATOR): Pts with AMI treated with Primary PCI and current medical therapy

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Antibiotic Treatment Duration for Non-Surgically-Treated Diabetic Foot Osteomyelitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* diabetic patients treated non-surgically (i.e. without amputation or resection of the infected bone) for an osteomyelitis of the foot complicating a neuropathic foot without ischemia of the foot defined as the absence of any pedal pulse. Patients aged of 18 years or more were included if they had type 2 diabetes and osteomyelitis of the foot (i.e.below the ankle).~Exclusion Criteria:~* Patients with gangrene or who require bone resection or amputation when osteomyelitis of the foot was diagnosed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- antibiotic therapy (Type: ACTIVE_COMPARATOR): patients are treated with a 6 week-duration of antibiotic therapy :~* Rifampin IP and PO twice daily, 10mg/kg /12H~* Levofloxacin IV and PO 500-750mg once daily~* Doxycycline PO 200mg once daily~* Trimethoprim- sulfamethoxazole IV and PO 800/160mg thrice daily~* Fusidic acid PO 500mg twice daily~* Linezolid IV and PO 600mg twice daily~* Ciprofloxacin IV and PO 750to 1000mg/12h~* Cefotaxime IV 100mg/kg in three IV infusions daily~* Ceftriaxone IV,intramuscularly or subcutaneously 2g once daily~* Cefepime IV ou intra-muscularly 2g /8-12h
- 12 week-duration of antibiotic therapy (Type: ACTIVE_COMPARATOR): patients are treated with a 12 week-duration of antibiotic therapy :~* Rifampin IP and PO twice daily, 10mg/kg /12H~* Levofloxacin IV and PO 500-750mg once daily~* Doxycycline PO 200mg once daily~* Trimethoprim- sulfamethoxazole IV and PO 800/160mg thrice daily~* Fusidic acid PO 500mg twice daily~* Linezolid IV and PO 600mg twice daily~* Ciprofloxacin IV and PO 750to 1000mg/12h~* Cefotaxime IV 100mg/kg in three IV infusions daily~* Ceftriaxone IV,intramuscularly or subcutaneously 2g once daily~* Cefepime IV ou intra-muscularly 2g /8-12h

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Randomized Trial of 24 or 48 Weeks of Peginterferon Alfa-2a Plus Ribavirin for HCV Genotype 1-infected Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Treatment naïve~* Age 18 and older than 18 years old~* Anti-HCV (Abbott HCV EIA 2.0, Abbott Diagnostic, Chicago, IL) positive \> 6 months~* Detectable serum quantitative HCV-RNA (Cobas Amplicor HCV Monitor v2.0, Roche Molecular Systems, Pleasanton, CA) with dynamic range 600\~\<500,000 IU/ml~* HCV genotype 1 (Inno-LiPA HCV II, Innogenetics, Ghent, Belgium)~* Serum alanine aminotransferase levels above the upper limit of normal with 6 months of enrollment~* A liver biopsy consistent with the diagnosis of chronic hepatitis C~Exclusion Criteria:~* Anemia (hemoglobin \< 13 gram per deciliter for men and \< 12 gram per deciliter for women)~* Neutropenia (neutrophil count \<1,500 per cubic milliliter)~* Thrombocytopenia (platelet \<90,000 per cubic milliliter)~* Co-infection with hepatitis B virus (HBV) or human immunodeficiency virus (HIV)~* Chronic alcohol abuse (daily consumption \> 20 gram per day)~* Decompensated liver disease (Child-Pugh class B or C)~* Serum creatinine level more than 1.5 times the upper limit of normal~* Autoimmune liver disease~* Neoplastic disease~* An organ transplant~* Immunosuppressive therapy~* Poorly controlled autoimmune diseases, pulmonary diseases, cardiac diseases, psychiatric diseases, neurological diseases, diabetes mellitus~* Evidence of drug abuse~* Unwilling to have contraception

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Peginterfron and ribavirin (24 weeks) (Type: ACTIVE_COMPARATOR): Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (\<75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) for 24 weeks
- Peginterferon and ribavirin (48 weeks) (Type: ACTIVE_COMPARATOR): Pegylated interferon alfa-2a (Pegasys, F. Hoffmann-LaRoche) 180 ug/week plus ribavirin (Robatrol, F. Hoffmann-LaRoche) 1000-1200 mg/day (\<75 kg, 1000 mg/day; \>= 75 kg, 1200 mg/day) for 48 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Tanezumab in Osteoarthritis Of The Hip

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Osteoarthritis of the hip according to ACR criteria with Kellgren-Lawrence x-ray grade of 2~* Unwilling or unable to take non-opiate pain medications, for whom non-opiate pain medications have not provided adequate pain relief or are candidates for Hip injections, arthroplasty or replacement surgery~* Pain level and function levels as required by the protocol at Screening and Baseline~* Willing to discontinue pain medications (acetaminophen will be permitted up to a certain level) before and during the study~* Must agree to the contraceptive requirements of the protocol if applicable~* Must agree to the treatment plan, scheduled visits, and procedures of the protocol~Exclusion Criteria:~* Pregnancy~* BMI greater than 39~* Other severe pain, significant cardiac, neurological or psychological conditions, or above the protocol limits for laboratory and blood pressure results

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- Tanezumab 10 mg (Type: EXPERIMENTAL): Tanezumab 10 mg IV every 8 weeks
- Tanezumab 5 mg (Type: EXPERIMENTAL): Tanezumab 5mg IV every 8 weeks
- Tanezumab 2.5 mg (Type: EXPERIMENTAL): Tanezumab 2.5 mg IV every 8 weeks.
- Placebo (Type: EXPERIMENTAL): Placebo

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Nerve Growth Factor for the Treatment of Cornea Disease

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~Patients diagnosed with LSCD and neurotrophic cornea confirmed by testing with Cochet-Bonnet aesthesiometer~Exclusion Criteria:~1. Active ocular infection~2. Anticipated need for bandage contact lens, amniotic membrane graft, or tarsorrhaphy during the study period~3. Unable to discontinue the use of contact lens~4. Visual acuity worse than 20/200 in the better eye

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: N-Acetyl Glucosamine as Therapeutic Intervention for Coronavirus Disease-19 (COVID-19)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* ≥18 years old~* Treated with N-acetyl glucosamine (NAG) as first-line treatment~* Present with coronavirus disease 2019 (COVID-19) symptoms (including but not limited to fever, cough, shortness of breath, sore throat, nasal congestion, malaise, headache, muscle pain, loss of taste and/or smell, diarrhea, and vomiting)~* Clinically diagnosed with COVID-19 by reverse transcription polymerase chain reaction (RT-PCR)~* No intubation prior to hospitalization and enrollment in the current study.~Exclusion Criteria:~* \<18 years old upon admission~* Allergy to NAG~* Allergy to shellfish~* Currently taking warfarin~* Currently pregnant or lactating

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 90 Years
- Healthy Volunteers: f

Study Arms:
- N-Acetyl Glucosamine (Type: EXPERIMENTAL): All patients in the treatment arm of the study were treated with N-Acetyl Glucosamine, a potential therapy for Coronavirus Disease-19 (COVID-19).
- Control (Type: PLACEBO_COMPARATOR): All patients in the comparator arm were admitted to the same hospital with COVID-19 but did not receive N-Acetyl Glucosamine treatment. All these patients were identified retrospectively.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete